Last updated: 11/06/2026 11:30:14

A Study of Niraparib (GSK3985771) Maintenance Treatment in participants with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

GSK study ID
213359
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Trial status
Completed
Completed
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Trial description: This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer. Participants must have completed front-line platinum based regimen with complete response (CR) or partial response (PR). Data collection for Secondary Outcome measures is ongoing and the approximate duration of the study will be 7 years.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:

Progression Free Survival

Timeframe: Up to 34 months

Secondary outcomes:

Overall Survival

Timeframe: Up to 34 months

Time to First Subsequent Therapy (TFST)

Timeframe: Up to 34 months

Progression-Free Survival-2 (PFS2)

Timeframe: Up to 34 months

Change From Baseline in Participant Reported Outcome (PRO): Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI)

Timeframe: Baseline (Day 1, Pre-dose) and Up to Week 24

Change From Baseline in PRO: European Quality of Life Scale, 5-dimensions, 5-levels of Severity (EQ-5D-5L) Utility Score

Timeframe: Baseline (Day 1, Pre-dose) and Up to Week 24

Change From Baseline in Functional Scales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)

Timeframe: Baseline (Day 1, Pre-dose) and Up to Week 24

Change From Baseline in Global Health Status/QoL of EORTC-QLQ-C30

Timeframe: Baseline (Day 1, Pre-dose) and Up to Week 24

Change From Baseline in Symptoms Scales and Symptoms Items (Dyspnea, Appetite Loss, Insomnia, Constipation, Diarrhea and Financial Difficulty) of EORTC-QLQ-C30

Timeframe: Baseline (Day 1, Pre-dose) and Up to Week 24

Change From Baseline in Functional Scales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Ovarian Cancer Module (EORTC-QLQ-OV28)

Timeframe: Baseline (Day 1, Pre-dose) and Up to 34 months

Change From Baseline in Symptoms Scale of EORTC-QLQ-OV28

Timeframe: Baseline (Day 1, Pre-dose) and Up to 34 months

Interventions:
Drug: Niraparib
Drug: Placebo
Enrollment:
733
Primary completion date:
2019-17-05
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
B J Monk, M P Barretina-Ginesta, B Pothuri, I Vergote, W Graybill, M R Mirza, C C McCormick, D Lorusso, R G Moore, G Freyer, R E O'Cearbhaill, F Heitz, D M O'Malley, A Redondo, M S Shahin, C Vulsteke, W H Bradley, C A Haslund, D M Chase, C Pisano, L L Holman, M J Rubio Pérez, P DiSilvestro, L Gaba, T J Herzog, I Bruchim, N Compton, L Shtessel, I A Malinowska, A González-Martín. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2024-Sep-14; doi:10.1016/j.annonc.2024.08.2241 http://dx.doi.org/S0923-7534(24)03762-110.1016/j.annonc.2024.08.2241 PMID: 39284381 DOI: 10.1016/j.annonc.2024.08.2241
Medical condition
Ovarian Neoplasms
Product
Not applicable
Collaborators
Gynecologic Oncology Group, European Network of Gynaecological Oncological Trial Group (ENGOT), Myriad Genetics, Inc.
Study date(s)
July 2016 to July 2026
Type
Interventional
Phase
3

Participation criteria

Sex
Female
Age
18+ years
Accepts healthy volunteers
No
  • Participants must have histologically diagnosed high-grade serous or endometrioid, or high-grade predominantly serous or endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that is Stage III or IV according to Federation Internationale de Gynécologie et d’Obstétrique (FIGO) criteria.
  • Participants with inoperable Stage III and IV disease; All Stage IV participants with operable disease; Participants with stage III or IV disease treated with neoadjuvant chemotherapy and interval debulking surgery; and Participants with stage III disease who have visible residual disease after primary debulking surgery.
  • Participant has mucinous or clear cell subtypes of epithelial ovarian cancer, carcinosarcoma or undifferentiated ovarian cancer.
  • Participants with Stage III disease who have had complete cytoreduction (no visible residual disease) after primary debulking surgery.

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
BADALONA, Barcelona, Spain, 08916
Status
Study Complete
Location
GSK Investigational Site
Barcelona, Spain, 08003
Status
Study Complete
Location
GSK Investigational Site
Berlin, Berlin, Germany, 13353
Status
Study Complete
Location
GSK Investigational Site
Bern, Switzerland, 3010
Status
Study Complete
Location
GSK Investigational Site
Cordoba, Spain, 14004
Status
Study Complete
Location
GSK Investigational Site
Elche Alicante, Spain, 03203
Status
Study Complete
Location
GSK Investigational Site
Gent, Oost-Vlaanderen, Belgium, 9000
Status
Study Complete
Location
GSK Investigational Site
Göttingen, Niedersachsen, Germany, 37075
Status
Study Complete
Location
GSK Investigational Site
Heidelberg, Germany, 69120
Status
Study Complete
Location
GSK Investigational Site
L'HOSPITALET DE LLOBREGAT, Barcelona, Spain, 08907
Status
Study Complete
Location
GSK Investigational Site
Kuopio, Pohjois-Savo, Finland, 70210
Status
Study Complete
Location
GSK Investigational Site
Leuven, Belgium, 3000
Status
Study Complete
Location
GSK Investigational Site
Libramont, Belgium, 6800
Status
Study Complete
Location
GSK Investigational Site
Milano, Italy, 20133
Status
Study Complete
Location
GSK Investigational Site
Madrid, Spain, 28041
Status
Study Complete
Location
GSK Investigational Site
Tempe, AZ, United States, 85284
Status
Study Complete
Location
GSK Investigational Site
Milano, MI, Italy, 20132
Status
Study Complete
Location
GSK Investigational Site
Modena, Italy, 41100
Status
Study Complete
Location
GSK Investigational Site
München, Bayern, Germany, 81377
Status
Study Complete
Location
GSK Investigational Site
Namur, Belgium, 5000
Status
Study Complete
Location
GSK Investigational Site
Napoli, Italy, 80131
Status
Study Complete
Location
GSK Investigational Site
Odense C, Denmark, 5000
Status
Study Complete
Location
GSK Investigational Site
Oulu, Finland, 90029
Status
Study Complete
Location
GSK Investigational Site
Portsmouth, United Kingdom, PO6 3LY
Status
Study Complete
Location
GSK Investigational Site
STOCKHOLM, Sweden, SE-171 76
Status
Study Complete
Location
GSK Investigational Site
SAN SEBASTIÁN, Gipuzkoa, Spain, 20014
Status
Study Complete
Location
GSK Investigational Site
SEVILLA, Sevilla, Spain, 41013
Status
Study Complete
Location
GSK Investigational Site
Sevilla, Spain, 41014
Status
Study Complete
Location
GSK Investigational Site
Sheffield, South Yorkshire, United Kingdom, S10 2SJ
Status
Study Complete
Location
GSK Investigational Site
Tampere, Finland, 33521
Status
Study Complete
Location
GSK Investigational Site
The Woodlands, TX, United States, 77380-2794
Status
Study Complete
Location
GSK Investigational Site
Truro, Cornwall, United Kingdom, TR1 3LQ
Status
Study Complete
Location
GSK Investigational Site
UPPSALA, Sweden, SE-751 85
Status
Study Complete
Location
GSK Investigational Site
Valencia, Spain, 46010
Status
Study Complete
Location
GSK Investigational Site
Dunmore RoadWaterford, Ireland, N/A
Status
Study Complete
Location
GSK Investigational Site
Willow Grove, PA, United States, 19090
Status
Study Complete
Location
GSK Investigational Site
Zuerich, Switzerland, 8091
Status
Study Complete
Location
GSK Investigational Site
Angers cedex 9, France, 49000
Status
Study Complete
Location
GSK Investigational Site
Blackburn, Lancashire, United Kingdom, BB2 3HH
Status
Study Complete
Location
GSK Investigational Site
Frauenfeld, Switzerland, 8501
Status
Study Complete
Location
GSK Investigational Site
Galway, Ireland, H91 YR71
Status
Study Complete
Location
GSK Investigational Site
Grand Rapids, MI, United States, 49503
Status
Study Complete
Location
GSK Investigational Site
Hasselt, Belgium, 3500
Status
Study Complete
Location
GSK Investigational Site
London, United Kingdom, W12 0HS
Status
Study Complete
Location
GSK Investigational Site
Mannheim, Germany, 68167
Status
Study Complete
Location
GSK Investigational Site
Silver Spring, MD, United States, 20910-1460
Status
Study Complete
Location
GSK Investigational Site
Tel Aviv, Israel, 64239
Status
Study Complete
Location
GSK Investigational Site
Aalborg, Denmark, 9000
Status
Study Complete
Location
GSK Investigational Site
Barcelona, Spain, 08036
Status
Study Complete
Location
GSK Investigational Site
Barcelona, Spain, 8035
Status
Study Complete
Location
GSK Investigational Site
Basel, Switzerland, 4031
Status
Study Complete
Location
GSK Investigational Site
Bonheiden, Belgium, 2820
Status
Study Complete
Location
GSK Investigational Site
Bruxelles, Bruxelles, Belgium, 1000
Status
Study Complete
Location
GSK Investigational Site
Bruxelles, Belgium, 1200
Status
Study Complete
Location
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45136
Status
Study Complete
Location
GSK Investigational Site
Exeter, United Kingdom, EX2 5DW
Status
Study Complete
Location
GSK Investigational Site
Fuerth, Germany, 90766
Status
Study Complete
Location
GSK Investigational Site
Gent, Belgium, 9000
Status
Study Complete
Location
GSK Investigational Site
Girona, Spain, 17007
Status
Study Complete
Location
GSK Investigational Site
Edinburgh, United Kingdom, G12 0YN
Status
Study Complete
Location
GSK Investigational Site
Glasgow, United Kingdom, G12 0YN
Status
Study Complete
Location
GSK Investigational Site
Haifa, Israel, 38100
Status
Study Complete
Location
GSK Investigational Site
Herlev, Denmark, 2730
Status
Study Complete
Location
GSK Investigational Site
Koebenhavn, Denmark, 2100
Status
Study Complete
Location
GSK Investigational Site
Madrid, Spain, 28033
Status
Study Complete
Location
GSK Investigational Site
Madrid, Spain, 28046
Status
Study Complete
Location
GSK Investigational Site
New Orleans, LA, United States, 70121
Status
Study Complete
Location
GSK Investigational Site
Oslo, Norway, 0310
Status
Study Complete
Location
GSK Investigational Site
Springfield, MO, United States, 97477
Status
Study Complete
Location
GSK Investigational Site
Ramat Gan, Not applicable, Israel, 52621
Status
Study Complete
Location
GSK Investigational Site
Turku, Finland, 20520
Status
Study Complete
Location
GSK Investigational Site
Valencia, Spain, 46009
Status
Study Complete
Location
GSK Investigational Site
Zaragoza, Spain, 50009
Status
Study Complete
Location
GSK Investigational Site
Aachen, Nordrhein-Westfalen, Germany, 52074
Status
Study Complete
Location
GSK Investigational Site
Dublin 8, Ireland, 8
Status
Study Complete
Location
GSK Investigational Site
Hildesheim, Germany, 31134
Status
Study Complete
Location
GSK Investigational Site
Lecce, Italy, 73100
Status
Study Complete
Location
GSK Investigational Site
San Francisco, CA, United States, 94115
Status
Study Complete
Location
GSK Investigational Site
Indianapolis, IN, United States, 46237
Status
Study Complete
Location
GSK Investigational Site
Salt Lake City, UT, United States, 84112
Status
Study Complete
Location
GSK Investigational Site
West Harrison, NY, United States, 10604
Status
Study Complete
Location
GSK Investigational Site
Wilmington, NC, United States, 28401
Status
Study Complete
Location
GSK Investigational Site
New Haven, CT, United States, 06510
Status
Study Complete
Location
GSK Investigational Site
Tucson, AZ, United States, 85724
Status
Study Complete
Location
GSK Investigational Site
Tucson, AZ, United States, 85710
Status
Study Complete
Location
GSK Investigational Site
Covington, LA, United States, 70433
Status
Study Complete
Location
GSK Investigational Site
Kennewick, WA, United States, 99336
Status
Study Complete
Location
GSK Investigational Site
Tyler, TX, United States, 75701
Status
Study Complete
Location
GSK Investigational Site
Milwaukee, WI, United States, 53226
Status
Study Complete
Location
GSK Investigational Site
Neptune, NJ, United States, 07753-3036
Status
Study Complete
Location
GSK Investigational Site
Iowa City, IA, United States, 52242
Status
Study Complete
Location
GSK Investigational Site
Santa Rosa, CA, United States, 95403
Status
Study Complete
Location
GSK Investigational Site
Miami, FL, United States, 33136
Status
Study Complete
Location
GSK Investigational Site
Rochester, NY, United States, 14620
Status
Study Complete
Location
GSK Investigational Site
Columbus, OH, United States, 43210
Status
Study Complete
Location
GSK Investigational Site
Spokane, WA, United States, 99202
Status
Study Complete
Location
GSK Investigational Site
Philadelphia, PA, United States, 19104
Status
Study Complete
Location
GSK Investigational Site
Chapel Hill, NC, United States, 27599-7570
Status
Study Complete
Location
GSK Investigational Site
Providence, RI, United States, 02905
Status
Study Complete
Location
GSK Investigational Site
Mineola, NY, United States, 11501
Status
Study Complete
Location
GSK Investigational Site
Jacksonville, FL, United States, 32224-1865
Status
Study Complete
Location
GSK Investigational Site
Atlanta, GA, United States, 30342
Status
Study Complete
Location
GSK Investigational Site
Baltimore, MD, United States, 21215-5271
Status
Study Complete
Location
GSK Investigational Site
Savannah, GA, United States, 31404
Status
Study Complete
Location
GSK Investigational Site
Portland, OR, United States, 97210
Status
Study Complete
Location
GSK Investigational Site
Seattle, WA, United States, 98104
Status
Study Complete
Location
GSK Investigational Site
Sioux Falls, SD, United States, 57105-2108
Status
Study Complete
Location
GSK Investigational Site
Tulsa, OK, United States, 74146
Status
Study Complete
Location
GSK Investigational Site
Fort Worth, TX, United States, 76104
Status
Study Complete
Location
GSK Investigational Site
San Francisco, CA, United States, 94118
Status
Study Complete
Location
GSK Investigational Site
Charleston, SC, United States, 29425-8900
Status
Study Complete
Location
GSK Investigational Site
Oklahoma City, OK, United States, 73104-5418
Status
Study Complete
Location
GSK Investigational Site
Minneapolis, MN, United States, 55433
Status
Study Complete
Location
GSK Investigational Site
Burlington, MA, United States, 01805
Status
Study Complete
Location
GSK Investigational Site
New York, NY, United States, 10016-4744
Status
Study Complete
Location
GSK Investigational Site
Indianapolis, IN, United States, 46260-2046
Status
Study Complete
Location
GSK Investigational Site
Geneva, IL, United States, 60555
Status
Study Complete
Location
GSK Investigational Site
Samara, Russia, 443011
Status
Study Complete
Location
GSK Investigational Site
Irkutsk, Russia, 664035
Status
Study Complete
Location
GSK Investigational Site
St-Petersburg, Russia, 194017
Status
Study Complete
Location
GSK Investigational Site
Chelyabinsk, Russia, 454048
Status
Study Complete
Location
GSK Investigational Site
St Petersburg, Russia, 191104
Status
Study Complete
Location
GSK Investigational Site
Krasnoyarsk, Russia, 660133
Status
Study Complete
Location
GSK Investigational Site
Arkhangelsk, Russia, 163045
Status
Study Complete
Location
GSK Investigational Site
Kelowna, BC, Canada, V1Y 5L3
Status
Study Complete
Location
GSK Investigational Site
Toronto, ON, Canada, M5G 1X6
Status
Study Complete
Location
GSK Investigational Site
Vancouver, BC, Canada, V5Z 4E6
Status
Study Complete
Location
GSK Investigational Site
Montreal, QC, Canada, H3T 1E2
Status
Study Complete
Location
GSK Investigational Site
Montreal, QC, Canada, H2X 0A9
Status
Study Complete
Location
GSK Investigational Site
London, ON, Canada, N6A 4L6
Status
Study Complete
Location
GSK Investigational Site
Toronto, ON, Canada, M4N 3M5
Status
Study Complete
Location
GSK Investigational Site
Ivanovo, Russia, 153040
Status
Study Complete
Location
GSK Investigational Site
Kazan, Russia, 420029
Status
Study Complete
Location
GSK Investigational Site
Orenburg, Russia, 460021
Status
Study Complete
Location
GSK Investigational Site
Debrecen, Hungary, 4032
Status
Study Complete
Location
GSK Investigational Site
Augusta, GA, United States, 30912-0004
Status
Study Complete
Location
GSK Investigational Site
Montreal, QC, Canada, H4A 3J1
Status
Study Complete
Location
GSK Investigational Site
Ottawa, ON, Canada, K1Y 4E9
Status
Study Complete
Location
GSK Investigational Site
Charleroi, Hainaut, Belgium, 6000
Status
Study Complete
Location
GSK Investigational Site
Barrie, ON, Canada, L4M 6M2
Status
Study Complete
Location
GSK Investigational Site
Candiolo, Italy, 10060
Status
Study Complete
Location
GSK Investigational Site
Pierre Benite Cedex, France, 69495
Status
Study Complete
Location
GSK Investigational Site
Caen Cedex 5, France, 14076
Status
Study Complete
Location
GSK Investigational Site
Nice, France, 06189
Status
Study Complete
Location
GSK Investigational Site
Prague, Unmapped, 10034
Status
Study Complete
Location
GSK Investigational Site
St Petersburg, Russia, 197758
Status
Study Complete
Location
GSK Investigational Site
MONTPELLIER CEDEX 5, France, 34298
Status
Study Complete
Location
GSK Investigational Site
Saint-Herblain cedex, France, 44805
Status
Study Complete
Location
GSK Investigational Site
Dnipropetrovsk, Ukraine, 49102
Status
Study Complete
Location
GSK Investigational Site
Kyiv, Ukraine, 03022
Status
Study Complete
Location
GSK Investigational Site
Paris, France, 75020
Status
Study Complete
Location
GSK Investigational Site
Austin, TX, United States, 78731-4214
Status
Study Complete
Location
GSK Investigational Site
Teaneck, NJ, United States, 07666
Status
Study Complete
Location
GSK Investigational Site
Cleveland, OH, United States, 44124
Status
Study Complete
Location
GSK Investigational Site
Mayfield Hts, OH, United States, 44124
Status
Study Complete
Location
GSK Investigational Site
Cleveland, OH, United States, 44111-5605
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, CA, United States, 90095
Status
Study Complete
Location
GSK Investigational Site
Mirano, VE, Italy, 30035
Status
Study Complete
Location
GSK Investigational Site
Sint-Niklaas, Belgium, 9100
Status
Study Complete
Location
GSK Investigational Site
Ostrava, Unmapped, 708 52
Status
Study Complete
Location
GSK Investigational Site
Plzen, Unmapped, 30460
Status
Study Complete
Location
GSK Investigational Site
San Antonio, TX, United States, 78229
Status
Study Complete
Location
GSK Investigational Site
Warrenville, IL, United States, 60555
Status
Study Complete
Location
GSK Investigational Site
Hartford, CT, United States, 06102-8000
Status
Study Complete
Location
GSK Investigational Site
Rennes Cedex, France, 35042
Status
Study Complete
Location
GSK Investigational Site
Springfield, MA, United States, 01199
Status
Study Complete
Location
GSK Investigational Site
Staffordshire, United Kingdom, ST4 6QG
Status
Study Complete
Location
GSK Investigational Site
Paris, France, 75908
Status
Study Complete
Location
GSK Investigational Site
Middletown, NJ, United States, 07748
Status
Study Complete
Location
GSK Investigational Site
New York, NY, United States, 10065-6007
Status
Study Complete
Location
GSK Investigational Site
Morgantown, WV, United States, 26505-3494
Status
Study Complete
Location
GSK Investigational Site
Buffalo, NY, United States, 14263
Status
Study Complete
Location
GSK Investigational Site
Baton Rouge, LA, United States, 70817
Status
Study Complete
Location
GSK Investigational Site
Lublin, Poland, 20-090
Status
Study Complete
Location
GSK Investigational Site
Bath, United Kingdom, BA1 3NG
Status
Study Complete
Location
GSK Investigational Site
Dresden, Sachsen, Germany, 01307
Status
Study Complete
Location
GSK Investigational Site
Hamburg, Hamburg, Germany, 20246
Status
Study Complete
Location
GSK Investigational Site
Munchen, Germany, 81737
Status
Study Complete
Location
GSK Investigational Site
Poznan, Poland, 60-569
Status
Study Complete
Location
GSK Investigational Site
Petach Tikva, Israel, 49100
Status
Study Complete
Location
GSK Investigational Site
Beer Sheva, Israel, 84101
Status
Study Complete
Location
GSK Investigational Site
Olsztyn, Poland, 10-561
Status
Study Complete
Location
GSK Investigational Site
Vinnytsia, Ukraine, 21029
Status
Study Complete
Location
GSK Investigational Site
Krivoy Rog, Ukraine, 50048
Status
Study Complete
Location
GSK Investigational Site
Holon, Israel, 58100
Status
Study Complete
Location
GSK Investigational Site
Ivano-Frankivsk, Ukraine, 76000
Status
Study Complete
Location
GSK Investigational Site
Kherson, Ukraine, 73000
Status
Study Complete
Location
GSK Investigational Site
Zaporizhzhia, Ukraine, 69040
Status
Study Complete
Location
GSK Investigational Site
Gyor, Hungary, 9024
Status
Study Complete
Location
GSK Investigational Site
Madrid, Spain, 28034
Status
Study Complete
Location
GSK Investigational Site
Kharkiv, Ukraine, 61070
Status
Study Complete
Location
GSK Investigational Site
Surrey, BC, Canada, V3V 1Z2
Status
Study Complete
Location
GSK Investigational Site
Calgary, AB, Canada, T2N 4N2
Status
Study Complete
Location
GSK Investigational Site
Hinsdale, IL, United States, 60521
Status
Study Complete
Location
GSK Investigational Site
Pyatigorsk, Russia, 357502
Status
Study Complete
Location
GSK Investigational Site
Chicago, IL, United States, 60612
Status
Study Complete
Location
GSK Investigational Site
Springfield, MO, United States, 65807
Status
Study Complete
Location
GSK Investigational Site
Hollywood, FL, United States, 33323
Status
Study Complete
Location
GSK Investigational Site
Greenfield Park, QC, Canada, J4V 2H1
Status
Terminated/Withdrawn

Study documents

No study documents available.

Results overview

Results posted on ClinicalTrials.gov

Recruitment status
Completed
Actual primary completion date
2019-17-05
Actual study completion date
2026-06-07

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website